Lantheus Holdings, Inc. (NASDAQ: LNTH) is one of the Cheap Healthcare Stocks to Buy by 2026. As of December 7, Lantheus Holdings, Inc. (NASDAQ: LNTH) had a “Buy” or equivalent rating from nearly 80% of analysts covering the stock. With a median price target of $75, the stock has an upside potential of 18.48% from the current price.
On November 24, Jefferies analyst Matthew Taylor reiterated a Buy rating on Lantheus Holdings, Inc. (NASDAQ: LNTH), while maintaining the price target at $105, suggesting 66% upside potential.
Photography A and N/Shutterstock.com
Earlier on November 12, Leerink Partners reduced its price target on Lantheus Holdings, Inc. (NASDAQ: LNTH) from $97 to $90, with an “overweight” rating unchanged. The analyst believes that 340B pricing pressures and competitive dynamics will influence the company’s Pylarify franchise, leading to a downgraded outlook.
When Lantheus Holdings, Inc. (NASDAQ: LNTH) reported its third quarter results on November 6, the company reported mixed financial performance. Although revenue beat consensus expectations by around 5%, diluted EPS came in 2% below consensus expectations. Pylarify’s revenue decline was attributed to “better price compression based on 340 billion prices and competitive pressures from PET Ga-68 PSMA agents at large accounts.”
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a Massachusetts-based company specializing in diagnostic and therapeutic products for the treatment of a wide range of diseases. Incorporated in 1956, the company offers DEFINITY, TechneLite, Xenon-133 and Neurolite, among others.
While we recognize LNTH’s potential as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for a hugely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the reshoring trend, check out our free report on the best AI stock in the short term.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months And 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
